Premenstrual syndrome and premenstrual dysphoric disorder – problem on the border of psychiatry and gynecology
Keywords:
premenstrual dysphoric disorder, premenstrual syndromeAbstract
Many women in their reproductive years experiance some somatic and emotional symptoms in luteal phase of menstrual cycle. Clinically significant premenstrual symptoms occur in at least 20% of them. Many women in this group meet diagnostic criteria for premenstrual syndrom (PMS). Premenstrual disphoric disorder (PMDD) represents the more severe and disabling spectrum of premenstrual syndrome and occurs in an estimated 5% to 8% of menstruating women. The diagnosis of PMS/PMDD should be confirm by prospective symptoms charting in 2 menstrual cycles. It is essential to exclude other somatic or psychiatric disorders which symptoms can aggravate in luteal phase of cycle. The precise etiology of premenstrual syndroms is currently unknown. Recent evidence suggest that hypersensitivity to cyclical variations in level of gonadal hormones can predispose to PMS/PMDD. Dysregulation of serotoninergic and gabaergic neurotransmition are propably the consequence of this phenomenon. Several effective treatment option of that syndroms exist: serotoninergic antidepresant medications (selective serotonin reuptake inhibitors, venlafaxin, clomipramin), oral contraceptives that contain drosperinon and GnHR agonists. The present article provide a brief review of current information on the epidemiology, neurobiology and treatment of PMS/PMDD.
References
1. Mishell D.R. Jr. Premenstual disorders: epidemilogy and disease burden. Am. J. Manag. Care, 2005; 11( 16 Suppl): 473-479.
2. Dalton K,. Greene R. The premenstual syndrom. Br. Med J 1953; 91(1418):1007-1014.
3. Spitzer R.L., Severino S.K., Williams J.B., Parry B.L. Late luteal phase dysphoric disorder and DSM III. Am. J. Psychiatry, 1989; 146(7): 892-897.
4. World Health Organization (WHO). International classification of diseases. 10-th revision. Geneva; WHO: 1996.
5. American Collage of Obstetricians and Ginecologist. Premenstrual syndrom. Washington (DC):National Guideline Clearinghause; 2000.
6. American Psychiatric Association(APA).Diagnostic and statistical manual of mental diorders.4th edition.Wshington (DC) :APA 1994 :714-435.
7. Borenstein J.E., Dean B.B., Endicott J., Wong J., Brown C., Dickerson V., Yonkers K.A. Health and economic impact of premenstrual syndrome. J. Reprod. Med., 2003; 48(7): 515-524.
8. Kraemer G.R., Kraemer R.R. Premenstrual syndrom: diagnosis and treatment experiences. J. Womens Health, 1998; 7(7): 893-907.
9. Halbreich U., Borenstein J., Pearlstein T., Kahn L.S. The prevelance, impairment, impact, and burden of premenstrualdysphoric disorders (PMS/PMDD) Psychoneuroendocrinology, 2003; 28(Suppl 3): 1-23.
10. Cunningham J., Yonkers K.A., O'Brien S., Eriksson E. Update on research and treatment of premenstual dysphoric disorder. Harv. Rev. Psychiatry, 2009; 17(2): 120-137.
11. Endicott J., Nee J., Harrison Daily Record of severity of problems (DRSP) reliability and validity. Arch. Womens Ment. Health, 2006; 9(1): 41-49.
12. Feuerstein M., Shaw W.S.J. Measurement properties of the calendar of premenstrual experiance in patients with premenstrual syndrome. Reprod. Med., 2002; 47(4): 279-289.
13. Markum R.A. Assessment of reliability of and the effect of neutral instructions on the symptom rating on the Moon Menstrual Distress Questionaire. Psychosom. Med., 1976; 38(3): 163-172.
14. Thys-Jacobs S., Alvir J.M., Fratarcangelo P. Comparative analysis of three PMS assessment instruments - the identification of premenstrual syndrome with core symptoms. Psychopharmacol. Bull., 1995; 31(2): 389-396.
15. Pearlstein T., Yonkers K.A., Fayyad R., Gillespie J.A. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J. Affect Disord., 2005; 85(3): 275-282.
16. Meadem P.M., Hartlage S.A., Cook-Kerr J. Timing and severity of symptoms associated with the menstrual cycle in a community-based sample in the Midwestern United States. Psychiatry Res., 2005; 134(1): 27-36.
17. Bloch M., Schmidt P.J., Rubinow D.R. Premenstrual syndrome: evidence for symptom stability across cycles. Am. J. Psychiatry, 1997; 154(12): 1741-1746.
18. Kornstein S.G., Harvey A.T., Rush A.J., Wisniewski S.R., Trivedi M.H., Svikis D.S., McKenzie N.D., Bryan C., Harley R. Self-reported premenstrual exacerbation of depressive symptoms in patients seeking treatment for major depression. Psychol. Med., 2005; 35(5): 683-692.
19. Payne J.L., Roy P.S., Murphy-Eberenz K., Weismann M.M., Swartz K.L., McInnis M.G., Nwulia E., Mondimore F.M., MacKinnon D.F., Miller E.B., Nurnberger J.I., Levinson D.F., DePaulo J.R. Jr, Potash J.B. Reproductive cycle-associated mood symptoms in women with major depression and bipolar disorder. J. Affect. Disord., 2007; 99(1-3): 221-229.
20. Hartlange S.A., Arduino K.E., Gehlert S. Premenopausal dysphoric disorder and the risk of major depressive disorder: preliminary study J. Clin. Psychol., 2001; 57(12): 1571-1578.
21. Yonkers K A. Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders? J. Clin. Psychiatry, 1997; 58(Suppl 3): 62-67.
22. Case A.M., Reid R.L. Menstrual cycle effects on common medical conditions. Compr. Ther., 2001; 27(1): 65-71.
23. Pearlstein T., Stone A. Premenstrual syndrome. Psychiatr. Clin. North Am., 1998; 21(3): 577-590.
24. Clayton A.H.J. Symptoms related to the menstrual cycle: diagnosis, prevalence, and treatment. Psychiatr. Pract., 2008; 14(1): 13-21.
25. Dhingra V., Magnay J.L., O'Brien P.M., Chapman G., Fryer A.A., Ismail K.M. Serotonin receptor 1A C(-1019)G polymorphism associated with premenstrual dysphoric disorder. Obstet. Gynecol., 2007; 110(4): 788-792.
26. Huo L., Straub R.E., Roca C., Schmidt P.J., Shi K., Vakkalanka R., Weinberger D.R., Rubinow D.R. Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biol. Psychiatry, 2007; 62(8): 925-933.
27. Sundström P.I., Smith S., Gulinello M.. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch. Womens Ment. Health, 2003; 6(1): 23-41.
28. Wyatt K., Dimmock P., Jones P., Obhrai M., O'Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ, 2001; 323(7316): 776-780.
29. Hammarbäck S., Bäckström T., Holst J., von Schoultz B., Lyrenäs S. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement therapy. Acta Obstet. Gynecol. Scand., 1985; 64(5): 393-397.
30. Schmidt P.J., Nieman L.K., Danaceau M.A., Adams L.F., Rubinow D.R. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N. Engl. J. Med., 1998; 338(4): 209-216.
31. Andréen L., Nyberg S., Turkmen S., van Wingen G., Fernández G., Bäckström T. Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. Psychoneuroendocrinology, 2009; 34(8): 1121-1132.
32. Sundström I., Nyberg S., Bäckström T. Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology, 1997; 17(6): 370-381.
33. Björn I., Sundström-Poromaa I., Bixo M., Nyberg S., Bäckström G., Bäckström T. Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. J. Clin. Endocrinol. Metab., 2003; 88(5): 2026-2030.
34. Bethea C.L., Lu N.Z., Gundlah C., Streicher J.M. Diverse actions of ovarian steroids in the serotonin neural system. Front. Neuroendocrinol., 2002; 23(1): 41-100.
35. Freeman E.W., Rickels K., Sondheimer S.J., Polansky. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. M. Arch. Gen. Psychiatry, 1999; 56(10): 932-939.
36. Landén M., Eriksson O., Sundblad C., Andersch B., Naessén T., Eriksson E. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology (Berl), 2001; 155(3): 292-298.
37. Steinberg S., Annable L., Young S.N., Liyanage N. A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria. Biol. Psychiatry, 1999; 45(3): 313-320.
38. Menkes D.B., Coates D.C., Fawcett J.P. Acute tryptophan depletion aggravates premenstrual syndrome. J. Affect. Disord., 1994; 32(1): 37-44.
39. Roca C.A., Schmidt P.J., Smith M.J. Effects of metergoline on symptoms in women with premenstrual dysphoric disorder. Am. J. Psychiatry, 2002; 159(11): 1876-1881.
40. Inoue Y., Terao T., Iwata N., Okamoto K., Kojima H., Okamoto T., Yoshimura R., Nakamura J. Fluctuating serotonergic function in premenstrual dysphoric disorder and premenstrual syndrome: findings from neuroendocrine challenge tests. Psychopharmacology (Berl), 2007; 190(2): 213-219.
41. Pinna G., Costa E., Guidotti A. Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology (Berl), 2006; 186(3): 362-372.
42. Straneva P.A., Maixner W., Light K.C., Pedersen C.A., Costello N.L., Gridler S.S. Menstrual cycle, beta-endorphins, and pain sensitivity in premenstrual dysphoric disorder. Health Psychol., 2002; 21(4): 358-367.
43. Faratian B., Gaspar A.S., O'Brein P.M. Premenstrual syndrome: weight, abdominal swelling, and perceived body image. Am. J. Obstet. Ginecol., 1984; 150(2): 200-204.
44. Andersch B. Bromocriptine and premenstrual symptoms: a survey of double blind trials. Obstet. Gynecol. Surv., 1983; 38(11): 643-646.
45. Oksa S., Luukkaala T., Mäenpää J. Toremifene for premenstrual mastalgia: a randomised, placebo-controlled crossover study. BJOG, 2006; 113(6): 713-718.
46. Pearlstein T., Steiner M. Non-antidepressant treatment of premenstrual syndrome. J. Clin. Psychiatry, 2000; 61(Suppl 12): 22-27.
47. Bendich A. The potential for dietary supplements to reduce premenstrual syndrome (PMS) symptoms. J. Am. Coll. Nutr., 2000; 19(1): 3-12.
48. Parry B.L., Berga S.L., Mostofi N., Sependa P.A., Kripke D.F., Gillin J.C. Morning versus evening bright light treatment of late luteal phase dysphoric disorder. Am. J. Psychiatry, 1989; 146(9): 1215-1217.
49. Krasnik C., Montori V.M., Guyatt G.H. The effect of bright light therapy on depression associated with premenstrual dysphoric disorder. Am. J. Obstet. Ginecol., 2005; 193(3): 658-661.
50. Lustyk M.K., Gerrish W.G., Shaver S., Keys S.L. Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch. Womens Ment. Health, 2009; 12(2): 85-96.
51. Rapkin A.J., Winer S.A. The pharmacologic management of premenstrual dysphoric disorder. Expert. Opin. Pharmacother., 2008; 9(3): 429-445.
52. Landén M., Nissbrandt H., Allgulander C. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology, 2007; 32(1): 153-161.
53. Shah N.R., Jones J.B., Aperi J., Shemtov R., Karne A., Borenstein J. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder:a meta-analysis. Obstet. Gynecol., 2008; 111(5): 1175-1182.
54. Freeman E.W., Sondheimer S.J. Premenstrual Dysphoric Disorder: Recognition and Treatment. Prim. Care Companion J. Clin. Psychiatry, 2003; 5(1): 30-39.
55. Sundblad C., Wikander I., Andersch B., Eriksson E. A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment. Eur. Neuropsychopharmacol., 1997; 7(3): 201-206.
56. Sundblad C., Modigh K., Andersch B., Eriksson E. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr. Scand., 1992; 85(1): 39-47.
57. Sundblad C., Hedberg M.A., Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology, 1993; 9(2): 133-145.
58. Cohen L.S., Soares C.N., Lyster A., Cassano P., Brandes M., Leblanc G.A. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J. Clin. Psychopharmacol., 2004; 24(5): 540-543.
59. Freeman E.W., Rickels K., Yonkers K.A., Kunz N.R., McPherson M., Upton G.V. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet. Gynecol., 2001; 98(5 Pt 1): 737-744.
60. Freeman E.W., Sondheimer S.J., Rickels K. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol. Bull., 1997; 33(2): 303-309.
61. Brown C.S., Ling F.W., Andersen R.N., Farmer R.G., Arheart K.L. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet. Gynecol., 1994; 84(5): 779-786.
62. Leather A.T., Strudd J.W.W., Watson N.R., Holland E.F. The treatment of severe premenstrual syndrome with goserelin with and without 'add-back' estrogen therapy: a placebo-controlled study. Ginecol. Endocrinol., 1999; 13(1): 48-55.
63. Wyatt K.M., Dimmock P.W., Ismail K.M., Jones P.W., O'Brien P.M. The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: a meta analysis. BJOG, 2000; 111(6): 585-593.
64. Joffe H., Cohen L.S., Harlow B.L. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am. J. Obstet. Gynecol., 2003; 189(6): 1523-1530.
65. Graham C.A., Sherwin B.B. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J. Psychosom. Res., 1992; 36(3): 257-266.
66. Sulak P.J., Scow R.D., Preece C., Riggs M.W., Kuehl T.J. Hormone withdrawal symptoms in oral contraceptive users. Obstet. Gynecol., 2000; 95(2): 261-266.
67. Schlaff W.D., Lynch A.M., Hughes H.D., Cedars M.I., Smith D.L. Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression. Am. J. Obstet. Gynecol., 2004; 190(4): 943-951.
68. Sullivan H., Furniss H., Spona J., Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60microg) and ethinyl estradiol (15microg) on ovarian activity. Fertil. Steril., 1999; 72(1): 115-120.
69. Muhn P., Fuhrmann U., Fritzemeier K.H., Krattenmacher R., Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann. N. Y. Acad. Sci., 1995; 761: 311-335.
70. Yonkers K.A., Brown C., Pearlstein T.B., Foegh M., Sampson-Landers C., Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet. Gynecol., 2005; 106(3): 492-501.
71. Pearlstein T.B., Bachmann G.A., Zacur H.A., Yonkers K.A. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception, 2005; 72(6): 414-421.
72. Eriksson E., Sundblad C., Lisjö P., Modigh K., Andersch B. Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls. Psychoneuroendocrinology, 1992; 17(2-3): 195-204.
Downloads
Published
Issue
Section
License
Copyright (c) 2011 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
